Close
  Indian J Med Microbiol
 

Figure 1: Case no. 1: 60-year-old female patient discovered to have a right lobe focal mass during follow-up of chronic liver disease. (a) Arterial phase baseline triphasic computed tomography (CT): well-defined heterogeneously enhanced mass measuring 6 cm at segment VIII. (b) Portal phase baseline CT: contrast washout of the mass. (c) Arterial phase triphasic CT 4 weeks after transarterial chemoembolization (TACE): showed adequate lipidol deposition of half of the lesion with faint heterogenous contrast enhancement within the residual half of the lesion. (d) Portovenous phase CT 4 weeks after TACE: washed out of the lesion indicating residual active tumor tissue. (e) Arterial phase triphasic CT 2 weeks after radiofrequency ablation (RFA) of the residual active tumor tissue: no evidence of residual enhancing tissue. (f) Portovenous phase 2 weeks after RFA: no washout occurs (arrows) (complete response on mRECIST).

Figure 1: Case no. 1: 60-year-old female patient discovered to have a right lobe focal mass during follow-up of chronic liver disease. (a) Arterial phase baseline triphasic computed tomography (CT): well-defined heterogeneously enhanced mass measuring 6 cm at segment VIII. (b) Portal phase baseline CT: contrast washout of the mass. (c) Arterial phase triphasic CT 4 weeks after transarterial chemoembolization (TACE): showed adequate lipidol deposition of half of the lesion with faint heterogenous contrast enhancement within the residual half of the lesion. (d) Portovenous phase CT 4 weeks after TACE: washed out of the lesion indicating residual active tumor tissue. (e) Arterial phase triphasic CT 2 weeks after radiofrequency ablation (RFA) of the residual active tumor tissue: no evidence of residual enhancing tissue. (f) Portovenous phase 2 weeks after RFA: no washout occurs (arrows) (complete response on mRECIST).